Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy

Annals of Surgery

Volumn 226, Issue 1, 1997, Pages 6-16

  Morse, Michael A ^a   Zhou, Liang Ji ^a   Tedder, Thomas F ^a   Kim Lyerly, H ^a   Smith, Clay ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 3; RECOMBINANT INTERLEUKIN 4; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL MATURATION; CELL POPULATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CULTURE MEDIUM; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MIXED LYMPHOCYTE REACTION; MONONUCLEAR CELL; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD14; CATTLE; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; CULTURE MEDIA; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE CULTURE TEST, MIXED; MEMBRANE GLYCOPROTEINS; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030727328     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199707000-00002     Document Type: Article

References (43)

1. Moertel C, Fleming T, MacDonald J. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-358.
2. Early Breast Cancer Trialists' Collaborative Group: systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 3 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339:1-15.
3. Kalser M, Ellenberg S. Pancreatic cancer; adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120:899-903.
4. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982-990.
5. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991; 9:271-296.
6. Sornasse T, Flamand V, De Becker G, et al. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J Exp Med 1992; 175:15-21.
7. Steinman RM, Gutchinov B, Witmer M, et al. Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice. J Exp Med 1983; 157:613-627.
8. Macatonia SE, Taylor PM, Knight SC, et al. Primary stimulation by dendritic cell induces anti-viral proliferative and cytotoxic T cell responses in vitro. J Exp Med 1989; 169:1255-1264.
9. Xu H, Friedrichs U, Giesele R, et al. Human blood dendritic cells exhibit a distinct T-cell stimulating mechanism and differentiation pattern. Scand J Immunol 1992; 36:689-696.
10. Cohen PJ. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Immunol 1994; 24:315-319.
11. Porgador A, Gilboa E. Bone marrow generated dendritic cells pulsed with a class I restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995; 182:255-260.
12. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24:605-610.
13. Ossevort MA, Feltkamp MCW, van Veen KJH, et al. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother 1995; 18:86-94.
14. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1995; 12:1297-1302.
15. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996; 183:283-287.
16. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-58.
17. Steinman RM. Dendritic cells and immune-based therapies. Exp Hematol 1996; 24:859-862.
18. Reid CDL, Fryer PR, Clifford C, et al. Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood 1990; 76:1139-1149.
19. Egner W, Andreesen R, Hart D. Allostimulatory cells in fresh human blood. Transplantation 1993; 56:945-950.
20. Nestle F, Zheng X, Thompson C, et al. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J Immunother 1993; 151:6535-6545.
21. Young J, Steinman R. Accessory cell requirements for the mixed leukocyte reaction and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells. Cell Immunol 1988; 111:167-182.
22. Knight SC, Farrant J, Bryant A, et al. Non-adherent, low-density cells from human peripheral blood contain dendritic cells and monocytes, both with veiled morphology. Immunol 1986; 57:595-603.
23. Williams LA, Egner W, Hart DNJ. Isolation and function of human dendritic cells. Int Rev Cytol 1994; 153:41-103.
24. Thomas R, Davis L, Lipsky P. Isolation and characterization of human peripheral blood dendritic cells. J Immunol 1993; 150:821-834.
25. Van Voorhis W, Hair L, Steinman R, et al. Human dendritic cells: Enrichment and characterization from peripheral blood. J Exp Med 1982; 155:1172-1187.
26. Markowicz S, Engleman E. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990; 85:955-961.
27. Reid CDL, Stackpoole A, Meager A, et al. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 1992; 149:2681-2688.
28. Santiago-Schwarz F, Belilos E, Diamond B, et al. TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. J Leukoc Biol 1992; 52:274-281.
29. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176:1693-1702.
30. Santiago-Schwarz F, Divaris N, Kay C, et al. Mechanisms of tumor necrosis factor-a and granulocyte-macrophage colony-stimulating factor-induced dendritic cell development. Blood 1993; 82:3019-3028.
31. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
32. Szabolcs P, Moore MAS, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte macrophage colony-stimulating factor, and TNF-α. J Immunol 1995; 154:5851-5861.
33. Caux C, Dezutter-Dambuyant C, Schmitt D, et al. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360:258-261.
34. Zhou L-J, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A 1996; 93:2588-2592.
35. Caux C, Vandervliet B, Massacrier C, et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNFα. J Exp Med 1996; 184:695-706.
36. Zhou L-J, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 1995; 154:3821-3835.
37. Zhou L-J, Schwarting R, Smith H, et al. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig super-family. J Immunol 1992; 149:735-742.
38. Zhou L-J, Tedder TF. A distinct pattern of cytokine gene expression by human CD83+ Wood dendritic cells. Blood 1995; 86:3295-3301.
39. Hamilton JM, Chen AP, Nguyen B, et al. Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. Proc Am Soc Clin Oncol 1994; (abstract)961.
40. Rosenberg SA, Lotze MT, Muul LM, et al. A progress on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-897.
41. Boczkowski D, Nair S, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465-472.
42. Siena S, Di Nicola M, Bregni M, et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995; 23:1463-1471.
43. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor-α. J Exp Med 1994; 179:1109-1118.